Swedish Registry Links NOACs to Slower MMSE Decline in Alzheimer's with Atrial Fibrillation

The cohort comprised individuals with Alzheimer’s diagnosed after AFib, drawn from linked Swedish dementia, prescription, and inpatient registries. Researchers tracked MMSE scores for up to five years while balancing groups on age, comorbidity burden, and baseline cognition via propensity-score methods. NOAC exposure was associated with lower stroke incidence (HR 0.72 versus no treatment) and no excess major bleeding, whereas warfarin reduced strokes but raised bleeding risk.

Prior trials such as ARISTOTLE and ROCKET-AF established NOAC superiority for stroke prevention in AFib without dementia; the Swedish data extend this by showing an additional cognitive signal potentially mediated by fewer silent infarcts. However, residual confounding from unmeasured frailty or differential prescribing remains possible, and the absolute MMSE difference is modest.

A forthcoming RCT powered for both cognitive and clinical endpoints is required to confirm whether early NOAC initiation alters disease trajectory in comorbid populations. Regulatory bodies should consider dementia-specific subgroup analyses in future label updates.